<DOC>
	<DOCNO>NCT00003256</DOCNO>
	<brief_summary>Phase II trial study effectiveness flavopiridol treat patient recurrent prostate cancer hormone therapy . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Flavopiridol Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate clinical effectiveness flavopiridol patient metastatic androgen independent adenocarcinoma prostate . II . Assess toxic effect flavopiridol patient population . OUTLINE : Patients receive intravenous flavopiridol 72 hour every 2 week least 4 course . After 2 course treatment , patient experience unacceptable toxic effect may receive dose escalation . Patients follow every 3 month death .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>PATIENT CHARACTERISTICS : Performance Status : ECOG 02 Life Expectancy : At least 3 month WBC least 3,000/mm3 Absolute neutrophil count least 1,200/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8 g/dL Bilirubin great 1.5 mg/dL SGOT great 2.5 time normal Creatinine great 1.5 mg/dL Prostatespecific antigen least 10 ng/mL ( bone disease ) No prior concurrent maligancies within 5 year , except nonmelanoma skin cancer No serious medical illness No cord compression symptom PRIOR CONCURRENT THERAPY : No prior chemotherapy No prior suramin therapy Prior concurrent use luteinizing hormonereleasing hormone allow ( concurrent hormonal therapy ) No prior antiandrogen therapy within 4 week study At least 4 week since prior radiotherapy No prior strontium therapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>